205 Classifying study participants in clinical trials Supplementary Table S3. Inter-observer agreement between members of the expert panel for specific diagnostic labels in 60 validation cases Labels assigned (n = 173) Labels with agreement (n = 142) Concordance Κ (95% CI) Definite diagnostic labels 119 102 86% Respiratory tract infections 71 64 90% CAP 28 28 100% 1.00 (1.00-1.00) Influenza A/B 22 22 100% 1.00 (1.00-1.00) Other LRTI 11 6 55% 0.50 (0.12-0.88) HCAP 4 4 100% 1.00 (1.00-1.00) URTI 4 2 50% 0.48 (-0.13-1.10) Aspiration pneumonia 2 2 100% 1.00 (1.00-1.00) Radiation pneumonitis 0 - - - Other pulmonary diseases 31 26 84% Exacerbation COPD 16 12 75% 0.71 (0.46-0.97) Exacerbation asthma 13 12 92% 0.91 (0.75-1.08) Acute Chest Syndrome 0 - - - Atelectasis 0 - - - Exacerbation CF 0 - - - ILD 2 2 100% 1.00 (1.00-1.00) Pleural effusion or empyema 0 - - - Pleuritis sicca 0 - - - Pneumothorax 0 - - - Heart diseases 15 10 67% Cardiac failure* 8 6 75% 0.73 (0.38-1.08) Cardiac arrhythmias* 4 2 50% 0.49 (-0.11-1.09) ACS* 3 2 67% 0.66 (0.04-1.28) Pericarditis 0 - - - Stable angina pectoris 0 - - - Vascular disease 2 2 100% Pulmonary embolism 2 2 100% 1.00 (1.00-1.00) Nodules and tumors 0 - - Lung cancer and pulmonary metastases 0 - - - Mediastinal tumor 0 - - - Other diagnostic labels 57 40 70% Extrathoracic pathology 30 22 73% 0.65 (0.43-0.87) 8
RkJQdWJsaXNoZXIy MTk4NDMw